Hims(US:HIMS) Benzinga·2025-11-03 21:35Core Insights - Hims & Hers Health, Inc. shares increased following the release of its third-quarter earnings report, with the company actively discussing the availability of Novo Nordisk's oral Wegovy and Wegovy injections on its platform [1] Financial Performance - The company reported quarterly earnings of $0.06 per share, which fell short of the analyst estimate of $0.09 [2] - Quarterly revenue reached $598.97 million, exceeding the Street estimate of $580.24 million [2] Subscriber Growth - Hims & Hers' subscriber base grew to nearly 2.5 million, reflecting a 21% year-over-year increase [3] - The CEO emphasized the company's commitment to providing personalized care from home, indicating a focus on scaling and enhancing the platform [3] Future Outlook - For the fourth quarter, Hims & Hers projects revenue between $605 million and $625 million, slightly below the analyst estimate of $631.68 million [4] - The company has narrowed its fiscal 2025 revenue outlook to a range of $2.335 billion to $2.355 billion, compared to the estimate of $2.341 billion [4] - Hims & Hers Health stock rose by 6.44% to $47.28 in extended trading following the earnings report [4]